Look for profits with Regeneron

Regeneron, a US biotech company, specialises in treating eye diseases. But it’s far from a one-trick pony.


AMD is the main cause of blindness in over-65s

Bill Oxford

Diabetic eye disease and age-related macular degeneration (AMD) are becoming increasingly common. AMD is especially serious since it damages the central area of the retina, making it difficult to read and watch television; it is the leading cause of blindness in people over 65. Eylea, a drug produced by US biotech Regeneron (Nasdaq: REGN), is saving the sight of millions of people suffering from these conditions.

It is the market leader, notching up annual sales of $6.7bn a year, helped by its dosing regimen of injections every eight weeks compared to competing drug Lucentis's every four weeks. Analysts are pencilling in peak sales of $8bn a year for Eylea.

A full pipeline

Regeneron develops treatments for six main therapeutic areas: ophthalmology, inflammatory diseases, cardiovascular and metabolic diseases, oncology, pain and rare diseases. Beyond Eylea, approved and marketed drugs include Dupixent for atopic dermatitis and asthma, Zaltrap for metastatic colorectal cancer and Arcalyst for rare autoimmune conditions. Some of Regeneron's revenues appear as partnership revenues; these include non-US Eylea revenues through Bayer and sales of Zaltrap through Sanofi. The Sanofi sales totalled $1.4bn in 2018 with Eylea $6.75bn (US $4.1bn) and others $29.5m.

As with all biotech companies, Regeneron's potential is determined by the approved drugs likely to emerge from its pipeline. One of its most interesting pipeline areas is an immuno-oncology platform, with one drug, Libtayo, hitherto approved and marketed. Regeneron has nine of its 16 Phase I clinical trials in immuno-oncology with another two in later phases one each in Phase II and Phase III (the final stage of clinical testing, before a drug is submitted to regulators for approval).

Drugs close to approval

All but one of the 29 pipeline clinical trials are of antibody drugs based on antibodies developed in-house. A total of four new molecules entered clinical trials in 2018 and 4-6 new antibody molecules are expected to enter clinical trials during 2019 demonstrating that research and development is paying off. The Regeneron genetics centre, meanwhile, continues to make discoveries including a new genetic variant that protects against chronic liver disease.

A blockbuster machine going cheap

Regeneron (NASDAQ: REGN)
Investment measureInvestment ratio
Share price$3222020 p/e ratio12.8
Market value$34.5bnCash$5.6bn
Recent results20172018Change
Operating profit$2.08bn$2.53bn+21.6%*
Earnings per share$16.30$22.80+39.9%

earnings per share (EPS)

Research and development (R&D) is a very high 32.6% of sales compared to most biopharma companies which typically devote 15%-25% of sales to R&D (Merck, for example, invested 23% in 2018 and Pfizer 14.9%).

Regeneron also has a healthy cash balance of $5.6bn, which it can use both for advancing the pipeline and for acquiring smaller biotechs. After Eylea, Dupixent is the second-highest selling approved drug with sales of $374m in the first quarter of 2019. It is thus already a blockbuster drug (one with annual sales over $1bn). Dupixent was approved for asthma late last year and has just been given the green light to treat adolecent atopic dermatitis. It could soon be approved for chronic rhinitis too.

These approvals suggest increasing revenue through to at least 2020. Analysts project EPS for Regeneron of $23.1 for 2019, rising to $25.2 for 2020. This gives a forward P/E of 12.8 for 2020 at the recent share price of $322.

Regeneron has one super-blockbuster ($10bn+ sales), Eylea, and one blockbuster, Dupixent, already on the market, five other approved drugs, a substantial cash pile and a pipeline based on its own antibodies with impressive potential in immuno-oncology.

It has proprietary technologies for therapeutic antibody production and gene therapy. The main risk with this stock is of late-stage clinical trial failures that reduce the prospects of replacing and enhancing Eylea revenue should stronger competitors to Eylea emerge and for when Eylea's patents expire. But the forward price/earnings ratio of 12.8 makes Regeneron an attractive addition to your biopharma portfolio.

Most Popular

Are UK house prices set to fall? It’s not so simple
House prices

Are UK house prices set to fall? It’s not so simple

Figures suggest UK house prices are starting to slide, but we shouldn’t take these numbers at face value, explains Rupert Hargreaves.
11 Aug 2022
Is gold cheap relative to equities?
Gold price

Is gold cheap relative to equities?

Dominic Frisby looks at the Dow-gold ratio and explains why gold is starting to appear inexpensive compared to equities.
12 Aug 2022
The energy price cap keeps rising - here is what you can do about it
Personal finance

The energy price cap keeps rising - here is what you can do about it

The energy price cap could hit £5,000 next year, even higher than expected, predicts energy consultancy Auxilione. Saloni Sardana explains what you ca…
12 Aug 2022